HUE053273T2 - Opioid készítmények - Google Patents

Opioid készítmények

Info

Publication number
HUE053273T2
HUE053273T2 HUE13744494A HUE13744494A HUE053273T2 HU E053273 T2 HUE053273 T2 HU E053273T2 HU E13744494 A HUE13744494 A HU E13744494A HU E13744494 A HUE13744494 A HU E13744494A HU E053273 T2 HUE053273 T2 HU E053273T2
Authority
HU
Hungary
Prior art keywords
opioid preparations
opioid
preparations
Prior art date
Application number
HUE13744494A
Other languages
English (en)
Hungarian (hu)
Inventor
Fredrik Tiberg
Ian Harwigsson
Markus Johnsson
Original Assignee
Camurus Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53487482&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE053273(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US13/558,463 external-priority patent/US20130190341A1/en
Application filed by Camurus Ab filed Critical Camurus Ab
Publication of HUE053273T2 publication Critical patent/HUE053273T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dental Preparations (AREA)
HUE13744494A 2012-07-26 2013-07-26 Opioid készítmények HUE053273T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/558,463 US20130190341A1 (en) 2004-06-04 2012-07-26 High bioavailability opioid formulations
US201361806185P 2013-03-28 2013-03-28

Publications (1)

Publication Number Publication Date
HUE053273T2 true HUE053273T2 (hu) 2021-06-28

Family

ID=53487482

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13744494A HUE053273T2 (hu) 2012-07-26 2013-07-26 Opioid készítmények

Country Status (20)

Country Link
US (3) US20240226091A9 (cg-RX-API-DMAC7.html)
JP (1) JP6417327B2 (cg-RX-API-DMAC7.html)
CN (1) CN109010255B (cg-RX-API-DMAC7.html)
AU (3) AU2016244271B2 (cg-RX-API-DMAC7.html)
CL (1) CL2015000197A1 (cg-RX-API-DMAC7.html)
CY (1) CY1124016T1 (cg-RX-API-DMAC7.html)
DK (1) DK2877155T3 (cg-RX-API-DMAC7.html)
EA (1) EA034855B1 (cg-RX-API-DMAC7.html)
ES (1) ES2837803T3 (cg-RX-API-DMAC7.html)
HK (1) HK1221636A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20210068T1 (cg-RX-API-DMAC7.html)
HU (1) HUE053273T2 (cg-RX-API-DMAC7.html)
IL (3) IL296882A (cg-RX-API-DMAC7.html)
LT (1) LT2877155T (cg-RX-API-DMAC7.html)
MX (2) MX387722B (cg-RX-API-DMAC7.html)
MY (1) MY189481A (cg-RX-API-DMAC7.html)
NZ (2) NZ704012A (cg-RX-API-DMAC7.html)
PE (1) PE20150672A1 (cg-RX-API-DMAC7.html)
PT (1) PT2877155T (cg-RX-API-DMAC7.html)
SG (2) SG10201703964TA (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2837803T3 (es) 2012-07-26 2021-07-01 Camurus Ab Formulaciones de opioides
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
CN111432807A (zh) 2017-10-06 2020-07-17 铸造疗法股份有限公司 用于控制释放治疗剂的可植入贮库
CN111655303A (zh) 2018-01-08 2020-09-11 铸造疗法股份有限公司 经由治疗剂的控制递送用于治疗腔内癌症的装置、系统和方法
CN112367980A (zh) 2018-05-12 2021-02-12 铸造疗法股份有限公司 用于控制释放治疗剂的可植入贮库
WO2020047013A1 (en) 2018-08-28 2020-03-05 Foundry Therapeutics, Inc. Polymer implants
WO2020240018A1 (en) * 2019-05-29 2020-12-03 Camurus Ab Administration device & regime
CA3211413A1 (en) * 2021-02-18 2022-08-25 Navin Saxena Research And Technology Private Limited Non-aqueous injectable composition for sustained release of buprenorphine and use thereof
CN117999079A (zh) * 2021-08-20 2024-05-07 苏州恩华生物医药科技有限公司 一种包含塞纳布啡的药物组合物

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3474101A (en) 1960-09-05 1969-10-21 Reckitt & Sons Ltd Thebaine and oripavine derivatives
GB1136214A (en) 1965-06-15 1968-12-11 Reckitt & Sons Ltd Thebaine and oripavine derivatives
GB8332556D0 (en) 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4610868A (en) 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
KR100225983B1 (ko) 1992-10-26 1999-10-15 클라우스-디터 홈메리히, 디트리히 빌헬름 샤흐트 마이크로캡슐의 제조 방법
CN1099868C (zh) 1993-11-16 2003-01-29 斯卡法玛公司 具有控制释放活性成分作用的囊
CA2186750C (en) 1994-03-30 2008-08-05 Jens Hansen Use of fatty acid esters as bioadhesive substances
CA2187353C (en) 1994-04-08 2007-05-22 Gerald L. Yewey Liquid delivery compositions
SE518578C2 (sv) 1994-06-15 2002-10-29 Gs Dev Ab Lipidbaserad komposition
DE19536246A1 (de) 1994-09-30 1996-04-04 Juergen Dr Regenold Pharmazeutische Zusammensetzung
FR2726762B1 (fr) 1994-11-10 1997-01-17 Oreal Composition cosmetique ou dermatologique sous forme d'une dispersion d'une phase huileuse dans une phase aqueuse stabilisee a l'aide de particules de gel cubique et son procede d'obtention
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
JPH11513393A (ja) 1995-10-12 1999-11-16 ジーエス ディベロップメント エービー 皮膚又は粘膜表面へのもしくは介する活性物質の投与用医薬組成物
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
SE511313C2 (sv) 1997-01-13 1999-09-06 Gs Dev Ab Komposition med reglerad frisättning innefattande fettsyraester av diacylglycerol
BE1011899A6 (fr) 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
SE9802528D0 (sv) 1998-07-13 1998-07-13 Gs Dev Ab Bone tissue restoring composition
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
JP3952617B2 (ja) 1998-12-11 2007-08-01 株式会社日立製作所 内燃機関の排ガス浄化装置，排ガス浄化方法及び排ガス浄化触媒
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
JP4659943B2 (ja) 2000-02-25 2011-03-30 帝三製薬株式会社 塩酸ブプレノルフィン含有貼付剤
US6455066B1 (en) 2000-03-10 2002-09-24 Epicept Corporation Intradermal-penetration agents for topical local anesthetic administration
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6936187B2 (en) 2001-02-21 2005-08-30 Matthew Lawrence Lynch Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
US6656385B2 (en) 2001-02-21 2003-12-02 The Procter & Gamble Company Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
US20030003144A1 (en) 2001-05-01 2003-01-02 Keller Brian C. Sustained release formulations for nifedipine, dextromethorphan, and danazol
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20040022820A1 (en) 2001-11-28 2004-02-05 David Anderson Reversed liquid crystalline phases with non-paraffin hydrophobes
AU2003240493B2 (en) 2002-05-31 2008-06-12 L. Molteni & C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. Implantable polymeric device for sustained release of buprenorphine
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CA2521420A1 (en) 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
ES2623881T3 (es) 2003-11-07 2017-07-12 Camurus Ab Composiciones de lípidos y péptidos catiónicos
WO2005110360A2 (en) 2004-05-18 2005-11-24 Phares Pharmaceutical Research N.V. Compositions for injection
NZ551990A (en) 2004-06-04 2011-01-28 Camurus Ab Liquid depot formulations
GB0412530D0 (en) 2004-06-04 2004-07-07 Camurus Ab Formulation
US8920782B2 (en) * 2005-01-14 2014-12-30 Camurus Ab Topical bioadhesive formulations
US9649382B2 (en) 2005-01-14 2017-05-16 Camurus Ab Topical bioadhesive formulations
JP5107725B2 (ja) * 2005-01-14 2012-12-26 カムルス エービー ＧｎＲＨ類似体製剤
AU2005325510B2 (en) 2005-01-21 2009-07-02 Camurus Ab Pharmaceutical lipid compositions
ES2399645T3 (es) 2005-06-06 2013-04-02 Camurus Ab Formulaciones de análogos de GLP-1
US20070265329A1 (en) 2006-05-12 2007-11-15 Devang Shah T Methods for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
US10960077B2 (en) * 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
CA2680825C (en) 2007-03-22 2013-10-29 Cytotech Labs, Llc Topical formulations having enhanced bioavailability
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
US8859579B2 (en) 2008-03-21 2014-10-14 Richard Andrew Sewell Compostions and methods for preventing and/or treating disorders associated with cephalic pain
GB0815435D0 (en) * 2008-08-22 2008-10-01 Camurus Ab Formulations
CN102307895A (zh) 2008-12-04 2012-01-04 里兰斯坦福初级大学理事会 用于治疗或预防麻醉药停药症状的方法和组合物
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
US8975270B2 (en) 2010-06-08 2015-03-10 Rb Pharmaceuticals Limited Injectable flowable composition comprising buprenorphine
GB2513267B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
US9168251B2 (en) 2010-09-03 2015-10-27 Zoetis Belgium S.A High dose buprenorphine compositions and use as analgesic
ES2984717T3 (es) 2011-05-25 2024-10-30 Camurus Ab Formulaciones de péptidos de liberación controlada
ES2645345T3 (es) 2011-12-05 2017-12-05 Camurus Ab Formulaciones de liberación controlada robustas
EP2877155B1 (en) 2012-07-26 2020-10-28 Camurus AB Opioid formulations
ES2837803T3 (es) 2012-07-26 2021-07-01 Camurus Ab Formulaciones de opioides
KR101586789B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
CN103142458B (zh) 2013-01-22 2015-09-09 莱普德制药有限公司 无成瘾性镇痛缓释递药系统的组方与制备方法
WO2014130887A1 (en) 2013-02-22 2014-08-28 Cedars-Sinai Medical Center Pancreatic insulin-producing beta-cell lines derived from human pluripotent stem cells
US9393211B2 (en) 2013-03-15 2016-07-19 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
KR102370470B1 (ko) 2013-03-15 2022-03-04 헤론 테라퓨틱스 인코포레이티드 폴리오르토에스테르 및 비프로톤성 용매의 조성물
US20140323517A1 (en) 2013-04-30 2014-10-30 Heron Therapeutics, Inc. Compositions and methods for injection of a biodegradable polymer-based delivery system
JP6476658B2 (ja) 2013-09-11 2019-03-06 ソニー株式会社 画像処理装置および方法
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
GB201419091D0 (en) 2014-10-27 2014-12-10 Camurus Ab Formulations
US10471052B2 (en) 2015-02-19 2019-11-12 Mymd Pharmaceuticals, Inc. Method of treating addictions to opioids
GB201516554D0 (en) 2015-09-18 2015-11-04 Camurus Ab Controlled-release formulations
US20180244592A1 (en) 2015-10-28 2018-08-30 Haldor Topsøe A/S Dehydrogenation of ethylbenzene to styrene
AU2019357036B2 (en) 2018-10-11 2024-11-14 Indivior Uk Limited Buprenorphine to treat respiratory depression

Also Published As

Publication number Publication date
US20240131021A1 (en) 2024-04-25
PT2877155T (pt) 2020-12-18
CL2015000197A1 (es) 2015-11-13
US12318379B2 (en) 2025-06-03
US12161640B2 (en) 2024-12-10
SG11201500554XA (en) 2015-02-27
US20240075024A1 (en) 2024-03-07
IL289157A (en) 2022-02-01
BR112015001548A2 (pt) 2017-07-04
JP6417327B2 (ja) 2018-11-07
SG10201703964TA (en) 2017-06-29
AU2016244271A1 (en) 2016-10-27
MY189481A (en) 2022-02-16
IL236762A0 (en) 2015-03-31
DK2877155T3 (da) 2021-01-18
US20250049783A1 (en) 2025-02-13
ES2837803T3 (es) 2021-07-01
PE20150672A1 (es) 2015-05-21
AU2017279657B2 (en) 2018-11-15
JP2015522649A (ja) 2015-08-06
MX387722B (es) 2025-03-18
AU2016244271B2 (en) 2018-01-18
US20240226091A9 (en) 2024-07-11
IL296882A (en) 2022-12-01
LT2877155T (lt) 2021-02-25
MX2015001033A (es) 2015-04-09
HRP20210068T1 (hr) 2021-03-05
CY1124016T1 (el) 2022-05-27
NZ735248A (en) 2018-10-26
NZ704012A (en) 2017-09-29
AU2019200982A1 (en) 2019-02-28
EA201590202A1 (ru) 2015-07-30
AU2019200982B2 (en) 2019-07-18
EA034855B1 (ru) 2020-03-30
CN109010255B (zh) 2022-10-21
HK1221636A1 (en) 2017-06-09
HK1205948A1 (en) 2015-12-31
CN109010255A (zh) 2018-12-18
AU2017279657A1 (en) 2018-01-18
MX361873B (es) 2018-12-18

Similar Documents

Publication Publication Date Title
FIC20230009I1 (fi) Relatlimabi
NO2021049I1 (no) Duvelisib
NO2021046I1 (no) Apalutamide
NO2019034I1 (no) lorlatinib
EP2763896A4 (en) UNMANUFACTURED AIRCRAFT WITH SEVERAL ROTORS
DK2859055T3 (da) Polymercoatings
EP2880683A4 (en) BVA INTERPOSER
DK2825087T3 (da) Otoscanner
EP2809145A4 (en) CHLOROPLAST TRANSIT PEPTIDES
EP2814472A4 (en) DITHIOAMINE REDUCING AGENTS
DK2839013T3 (da) Ikke-disruptiv-gen-targetering
EP2805877A4 (en) UNDER HOOD
DK2873977T3 (da) Dobbeltdækker-rørdispenser
DE112012006109A5 (de) Okklusionsschienenanordnung
DK2854722T3 (da) Stomipose
EP2816694A4 (en) FLAT CABLE WINDING DEVICE
DK2825157T3 (da) Aminosyrelipider
EP2809729A4 (en) Siloxane polyether copolymers
HUE053273T2 (hu) Opioid készítmények
EP2801315A4 (en) SCANNING ENDOSCOPE DEVICE
FR2991688B1 (fr) Biosolubilisant
DE112012006214T8 (de) Wulstringwickler
DK2831122T3 (da) Anthocyanidin-kompleks
DK2885638T3 (da) Molekylenet
DE112012005566T8 (de) Seltenerdnanoverbundmagnet